Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Lisbon – page 10

638 clinical trials in Lisbon, Portugal across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Lisbon at a glance
638
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

638 trials in Lisbon

Open in trial search

Systemic scleroderma+3

Recruiting

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren's disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Artiva Biotherapeutics Inc.

Irritable bowel syndrome

Recruiting

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide Hydrochloride
  • Sponsor:Biocodex

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bicara Therapeutics Inc.

Plasma cell myeloma

Recruiting

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Eikon Therapeutics Inc.

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Lobular breast carcinoma in situ+1

Recruiting

Comparison of Low-Dose Exemestane versus Low-Dose Tamoxifen for Breast Cancer Prevention in Postmenopausal Women at High Risk

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Exemestane
  • Sponsor:Ente Ospedaliero Ospedali Galliera Di Genova

Malignant melanoma

Recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Head and neck cancer

Recruiting

Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Johnson & Johnson Enterprise Innovation Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Lisbon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on head and neck cancer treatments and advanced lung cancer therapies, combining novel approaches with standard treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Mantle Cell Lymphoma
  • Non-small Cell Lung Cancer

Studies evaluate targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, with particular focus on psoriasis and systemic sclerosis treatments.

  • Psoriatic Arthritis
  • Sjögren's Syndrome
  • Plaque Psoriasis

Testing innovative biological therapies and novel treatment approaches.

03 Neurological Disorders

Studies examining treatments for Dravet Syndrome and Alzheimer's-related psychosis, focusing on improving patient quality of life.

  • Alzheimer's Disease Psychosis
  • Epilepsy Conditions

Investigating new therapeutic options for challenging neurological conditions.

04 Inflammatory Diseases

Research targeting Crohn's Disease and various inflammatory conditions, evaluating new treatment combinations.

  • Pyoderma Gangrenosum
  • Chronic Rhinosinusitis
  • Hidradenitis Suppurativa

Testing advanced therapies for chronic inflammatory conditions.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.